D
Benitec Biopharma Inc.
BNTC
$11.94
-$0.23-1.89%
D
Sell
4/29/2024Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index and total return index.
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index and total return index.
E
Sell
4/12/2024Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 4/12/2024 due to a decline in the volatility index.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 4/12/2024 due to a decline in the volatility index.
D
Sell
3/27/2024Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 3/27/2024 due to an increase in the total return index and volatility index.
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 3/27/2024 due to an increase in the total return index and volatility index.
E
Sell
3/7/2024Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 3/7/2024 due to a decline in the volatility index, total return index and valuation index.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 3/7/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
2/21/2024Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 2/21/2024 due to an increase in the total return index, volatility index and solvency index.
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 2/21/2024 due to an increase in the total return index, volatility index and solvency index.
E
Sell
3/14/2023Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 03/14/2023.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/14/2023Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 2/14/2023 due to a decline in the growth index and solvency index. Debt to equity increased from 0.02 to 0.03, operating cash flow declined 44.45% from -$4.05M to -$5.84M, and EBIT declined 22.49% from -$4.58M to -$5.61M.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 2/14/2023 due to a decline in the growth index and solvency index. Debt to equity increased from 0.02 to 0.03, operating cash flow declined 44.45% from -$4.05M to -$5.84M, and EBIT declined 22.49% from -$4.58M to -$5.61M.
D
Sell
2/13/2023Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from E+ on 2/13/2023 due to an increase in the total return index and volatility index.
Benitec Biopharma Inc. (BNTC) was upgraded to D from E+ on 2/13/2023 due to an increase in the total return index and volatility index.
E
Sell
2/8/2023Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index.
D
Sell
12/1/2022Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 12/1/2022 due to a decline in the volatility index.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 12/1/2022 due to a decline in the volatility index.
D
Sell
11/16/2022Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 11/16/2022 due to an increase in the growth index and solvency index. The quick ratio increased from 1.61 to 5.49, debt to equity declined from 0.09 to 0.02, and earnings per share increased from -$0.6219 to -$0.47.
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 11/16/2022 due to an increase in the growth index and solvency index. The quick ratio increased from 1.61 to 5.49, debt to equity declined from 0.09 to 0.02, and earnings per share increased from -$0.6219 to -$0.47.
D
Sell
9/6/2022Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 9/6/2022 due to a major decline in the growth index, solvency index and total return index. Debt to equity increased from 0.03 to 0.09, total revenue declined 100% from $48 to $0, and the quick ratio declined from 4.52 to 1.61.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 9/6/2022 due to a major decline in the growth index, solvency index and total return index. Debt to equity increased from 0.03 to 0.09, total revenue declined 100% from $48 to $0, and the quick ratio declined from 4.52 to 1.61.
D
Sell
5/27/2022Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 5/27/2022 due to a large increase in the growth index. Total revenue increased 92% from $25 to $48, earnings per share increased from -$0.59 to -$0.4008, and EBIT increased 28.44% from -$4.84M to -$3.46M.
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 5/27/2022 due to a large increase in the growth index. Total revenue increased 92% from $25 to $48, earnings per share increased from -$0.59 to -$0.4008, and EBIT increased 28.44% from -$4.84M to -$3.46M.
D
Sell
5/5/2022Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index.
D
Sell
4/18/2022Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 4/18/2022 due to a decline in the volatility index and total return index.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 4/18/2022 due to a decline in the volatility index and total return index.
D
Sell
3/29/2022Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 3/29/2022 due to an increase in the volatility index.
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 3/29/2022 due to an increase in the volatility index.
D
Sell
3/4/2022Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 3/4/2022 due to a decline in the volatility index and total return index.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 3/4/2022 due to a decline in the volatility index and total return index.
D
Sell
2/16/2022Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 2/16/2022 due to an increase in the growth index and volatility index. Operating cash flow increased 21.83% from -$4.28M to -$3.34M, and earnings per share increased from -$0.6174 to -$0.59.
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 2/16/2022 due to an increase in the growth index and volatility index. Operating cash flow increased 21.83% from -$4.28M to -$3.34M, and earnings per share increased from -$0.6174 to -$0.59.
D
Sell
1/26/2022Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 1/26/2022 due to a decline in the total return index and volatility index.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 1/26/2022 due to a decline in the total return index and volatility index.
D
Sell
12/23/2021Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 12/23/2021 due to an increase in the total return index, volatility index and valuation index.
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 12/23/2021 due to an increase in the total return index, volatility index and valuation index.
D
Sell
11/22/2021Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 11/22/2021 due to a noticeable decline in the growth index, solvency index and total return index. The quick ratio declined from 14.46 to 9.83, EBIT declined 25.08% from -$3.86M to -$4.82M, and earnings per share declined from -$0.5673 to -$0.6174.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 11/22/2021 due to a noticeable decline in the growth index, solvency index and total return index. The quick ratio declined from 14.46 to 9.83, EBIT declined 25.08% from -$3.86M to -$4.82M, and earnings per share declined from -$0.5673 to -$0.6174.
D
Sell
11/9/2021Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
Benitec Biopharma Inc. (BNTC) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
E
Sell
11/8/2021Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index and total return index.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index and total return index.
D
Sell
9/10/2021Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 9/10/2021 due to an increase in the volatility index.
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 9/10/2021 due to an increase in the volatility index.
D
Sell
8/25/2021Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 8/25/2021 due to a decline in the volatility index and total return index.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 8/25/2021 due to a decline in the volatility index and total return index.
D
Sell
8/10/2021Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 8/10/2021 due to an increase in the volatility index.
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 8/10/2021 due to an increase in the volatility index.
D
Sell
7/23/2021Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 7/23/2021 due to a decline in the total return index and volatility index.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 7/23/2021 due to a decline in the total return index and volatility index.
D
Sell
7/8/2021Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 7/8/2021 due to an increase in the volatility index.
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 7/8/2021 due to an increase in the volatility index.
D
Sell
6/22/2021Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 6/22/2021 due to a decline in the volatility index.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 6/22/2021 due to a decline in the volatility index.
D
Sell
6/7/2021Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 6/7/2021 due to an increase in the volatility index and total return index.
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 6/7/2021 due to an increase in the volatility index and total return index.
D
Sell
5/17/2021Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 5/17/2021 due to a decline in the growth index, volatility index and solvency index. Debt to equity increased from 0.01 to 0.02, the quick ratio declined from 18.01 to 4.91, and EBIT declined 16.39% from -$3.26M to -$3.79M.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 5/17/2021 due to a decline in the growth index, volatility index and solvency index. Debt to equity increased from 0.01 to 0.02, the quick ratio declined from 18.01 to 4.91, and EBIT declined 16.39% from -$3.26M to -$3.79M.
D
Sell
5/7/2021Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 5/7/2021 due to an increase in the volatility index and total return index.
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 5/7/2021 due to an increase in the volatility index and total return index.
D
Sell
4/12/2021Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 4/12/2021 due to a decline in the volatility index.
Benitec Biopharma Inc. (BNTC) was downgraded to D- from D on 4/12/2021 due to a decline in the volatility index.
D
Sell
3/25/2021Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 3/25/2021 due to a noticeable increase in the growth index, solvency index and total return index. The quick ratio increased from 7.33 to 18.01, earnings per share increased from -$2.4522 to -$0.76, and debt to equity declined from 0.03 to 0.01.
Benitec Biopharma Inc. (BNTC) was upgraded to D from D- on 3/25/2021 due to a noticeable increase in the growth index, solvency index and total return index. The quick ratio increased from 7.33 to 18.01, earnings per share increased from -$2.4522 to -$0.76, and debt to equity declined from 0.03 to 0.01.
D
Sell
1/27/2021Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 1/27/2021 due to an increase in the volatility index and total return index.
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 1/27/2021 due to an increase in the volatility index and total return index.
E
Sell
1/7/2021Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 1/7/2021 due to a decline in the volatility index and total return index.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 1/7/2021 due to a decline in the volatility index and total return index.
D
Sell
12/23/2020Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 12/23/2020 due to an increase in the volatility index.
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 12/23/2020 due to an increase in the volatility index.
E
Sell
12/7/2020Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 12/7/2020 due to a decline in the volatility index, solvency index and total return index.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 12/7/2020 due to a decline in the volatility index, solvency index and total return index.
D
Sell
11/16/2020Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 11/16/2020 due to an increase in the growth index and valuation index. Total revenue increased 257.14% from -$35 to $55, operating cash flow increased 24.96% from -$3.15M to -$2.36M, and earnings per share increased from -$2.6705 to -$2.4522.
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 11/16/2020 due to an increase in the growth index and valuation index. Total revenue increased 257.14% from -$35 to $55, operating cash flow increased 24.96% from -$3.15M to -$2.36M, and earnings per share increased from -$2.6705 to -$2.4522.
E
Sell
9/25/2020Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 9/25/2020 due to a decline in the volatility index, efficiency index and growth index. Total revenue declined 225% from $28 to -$35, net income declined 39.63% from -$2.1M to -$2.94M, and EBIT declined 36.76% from -$2.11M to -$2.89M.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 9/25/2020 due to a decline in the volatility index, efficiency index and growth index. Total revenue declined 225% from $28 to -$35, net income declined 39.63% from -$2.1M to -$2.94M, and EBIT declined 36.76% from -$2.11M to -$2.89M.
D
Sell
9/10/2020Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 9/10/2020 due to an increase in the volatility index and efficiency index.
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 9/10/2020 due to an increase in the volatility index and efficiency index.
E
Sell
8/20/2020Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 8/20/2020 due to a decline in the efficiency index, solvency index and total return index. Debt to equity increased from 0.01 to 0.02, the quick ratio declined from 19.43 to 12.46, and net income declined 32.77% from -$1.58M to -$2.1M.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 8/20/2020 due to a decline in the efficiency index, solvency index and total return index. Debt to equity increased from 0.01 to 0.02, the quick ratio declined from 19.43 to 12.46, and net income declined 32.77% from -$1.58M to -$2.1M.
D
Sell
6/5/2020Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 6/5/2020 due to an increase in the volatility index and total return index.
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 6/5/2020 due to an increase in the volatility index and total return index.
E
Sell
5/19/2020Downgrade
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 5/19/2020 due to a decline in the volatility index.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from D- on 5/19/2020 due to a decline in the volatility index.
D
Sell
5/1/2020Upgraded
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 5/1/2020 due to a noticeable increase in the valuation index and total return index.
Benitec Biopharma Inc. (BNTC) was upgraded to D- from E+ on 5/1/2020 due to a noticeable increase in the valuation index and total return index.
E
Sell
4/24/2020None
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from U on 04/24/2020.
Benitec Biopharma Inc. (BNTC) was downgraded to E+ from U on 04/24/2020.
NASDAQ
04/10/2025 4:00PM Eastern
Quotes delayed
